To facilitate discussion, this paper describes various types of collections of specimens, their uses in research, types of identifiers, requirements for informed consent, third-party access to samples, recontact, and controversial ethical and social issues. There is need for public opinion research on people’s views of these issues, with particular attention to the views of minority groups.

1.
Lyons AS, Petrucelli RJ: Medicine: An Illustrated History. New York, Abrams, 1978, p 482.
2.
Annas GJ: Privacy rules for DNA databanks: Protecting coded ‘future diaries’. JAMA 1993;270:2346–2350.
3.
Clayton EW, Steinberg KK, Khoury MJ, Thomson E, Andrews L, Kahn MJE, Kopelman MJ, Weiss JO: Informed consent for genetic research on stored tissue samples. JAMA 1995;274:1786–1792.
4.
Gold RL, Lebel RR, Mearns EA, Dworkin RB, Hudro T, Burns JK: Model consent forms from DNA linkage and storage. Am J Med Genet 1993;47:1223–1224.
5.
Grody WW: Molecular pathology, informed consent, and the paraffin block. Diagn Mol Pathol 1995;4:155–157.
6.
Knoppers BM, Laberge CM: Research and stored tissues: Persons as samples, samples as persons. JAMA 1995;22:1806–1807.
7.
Knoppers BM, Caulfield T, Kinsella TD: Legal Rights and Human Genetic Material. Toronto, Emond Montgomery, 1996.
8.
Stephenson J: Pathologists enter debate on consent for genetic research and stored tissue. JAMA 1996;275:503–504.
9.
Sugarman J, Reisner EG, Kurtzberg J: Ethical aspects of banking placental blood for bone marrow transplants. JAMA 1995;274:1783–1785.
10.
Therrell BL, Hannon WH, Pass KA, Lacey F, Brokopp C, Eckman J, Glass M, Heidenreich R, Kinney S, Kling S, Landenburger G, Meaney FJ, McCabe ERB, Panny S, Schwartz M, Shapira E: Guidelines for the Retention, Storage, and Use of Residual Dried Blood Spot Samples after Newborn Screening Analysis. Statement of the Council of Regional Networks for Genetic Services, 1996.
11.
Weir RF, Horton JR: DNA banking and informed consent. Part I. IRB: A review of human subjects research. IRB 1995;17(4):1–4.
12.
Clinical Laboratory Improvement Amendments, 1996. Clinical Laboratory Improvement Amendments of 1988 (CLIA). 42 Code of Federal Regulations 493 (10-1-96), pp 796–921.
13.
National Bioethics Advisory Commission. Research Involving Human Biological Materials. Ethical Issues and Policy Guidance. Rockville, August 1999.
14.
Hiller EH, Landenburger G, Natowicz MR: Public participation in medical policy-making and the status of consumer autonomy: The example of newborn-screening programs in the United States. Am J Public Health 1997;87:1280–1288.
15.
McEwen J: Forensic DNA data banking by state crime laboratories. Am J Hum Genet 1995;56:1487.
16.
McEwen JE, Reilly PR: A review of state legislation on DNA forensic data banking. Am J Hum Genet 1994;54:941–958.
17.
United States, Federal Bureau of Investigation: Crime in the United States, 1996. Washington, FBI, 1997.
18.
United States, Department of Justice, Bureau of Justice Statistics: Lifetime Likelihood of Going to State or Federal Prison. Washington, US Government Printing Office, March 1997, pp 8–10.
19.
United States, Assistant Secretary of Defense (Health Affairs) Memorandum and Policy Statement. Establishment of a repository of specimen samples to aid in remains identification using genetic deoxyribonucleic acid (DNA) analysis. Washington, January 5, 1993.
20.
United States, Assistant Secretary of Defense (Health Affairs), Memorandum. Policy refinements for the Armed Forces Repository of Specimen Samples for the Identification of Remains, April 2, 1996.
21.
Greely HT: The ethics of the Human Genome Diversity Project: The North American Regional Committee’s Proposed Model Ethical Protocol: in Knoppers BM, Laberge CM, Hirtle M (eds): Human DNA: Law and Policy. The Hague, Kluwer Law International, 1997, pp 239–256.
22.
National Institute of Drug Abuse (NIH): Genetics of Drug Addiction Vulnerability, RFA DA-99-003, September 15, 1998.
23.
National Human Genome Research Institute – Department of Energy Guidance on Human Subjects Issues in Large-Scale DNA Sequencing. http://www.nhgri.nih.gov:80/Grant_info/Funding/Statements/RFA/humansubjects.htm.
24.
McEwen JE, Reilly PR: Stored Guthrie cards as DNA banks. Am J Hum Genet 1994;55:196–200.
25.
Gozal D, Lorey F: Incidence of sudden death syndrome in infants with sickle cell trait. J Pediatr 1994;124:211–214.
26.
Shaw GM, Todoroff K, Finnell RH, Lammer EJ, Leclerc D, Gravel RA, Rozen R: Infant methionine synthase variants and risk for spina bifida. J Med Genet, in press.
27.
Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ: Maternal vitamin use, genetic variation of infant methylene-tetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol 1995;148:30.
28.
Zhang Y-H, Ybarra A, McCabe L, Lorey F, Riggle S, Morales D, Naylor EW, Cunningham GC, McCabe ERB: Frequency of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency among California children dying of sudden infant death syndrome (SIDS) or liver disease. Two-tiered analysis of newborn screening specimens. Pediatr Res 1995;37:167A.
29.
Rothenberg KH, Rutkin AB: Toward a framework of mutalism: The Jewish community in genetics research. Community Genet 1998;1:148–153.
30.
Human Genome Organization, Statement on DNA Sampling: Control and Access, 1998. Genome Digest, 1999.
31.
World Health Organization, Hereditary Disease Programme. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services. Geneva, WHO, 1998.
32.
Canada, Tri-Council Working Group: Code of Conduct for Research Involving Humans. Ottawa, Minister of Supply and Services Canada, March 1996, sections 15.6 and 17.
33.
Tapping Iceland’s DNA. Science 1997;278:566.
34.
Strauss S: A tiny island yields a key to asthma. The Globe and Mail (Toronto, Canada), Nov 27, 1997, p A12.
35.
Foster MW, Bernstein D, Carter TH: A model agreement for genetic research in socially identifiable populations. Am J Hum Genet 1998;63:696–702.
36.
Juengst ET: Groups as gatekeepers to genomic research: Conceptually confusing, morally hazardous, and practically useless. Kennedy Inst Ethics J 1998;183–200.
37.
Wertz DC: Patient and professional views on autonomy: A survey in the United States and Canada. Health Law Rev 1998/99;7:9–10.
38.
Merz JF: Is genetics research minimal risk? IRB: A review of human subjects research. IRB 1996;18:7–8.
39.
American College of Medical Genetics, Storage of Genetic Materials Committee. Statement on storage and use of genetic materials. Am J Hum Genet 1995;57:1499–1500.
40.
American Society of Human Genetics: Ad hoc Committee on DNA Technology, DNA banking and DNA analysis: Points to consider. Am J Hum Genet 1988;42:781–783.
41.
Marshall E: Policy on DNA research troubles tissue bankers: Centers for Disease Control and Prevention develop ethical standards for genetic research on archived blood and tissue samples. Science 1996;271:440.
42.
Canadian College of Medical Geneticists. Policy Statement concerning DNA banking and molecular genetic diagnosis. Clin Invest Med 1991;14:363.
43.
American Society of Human Genetics, Board of Directors, Statement on informed consent for genetic research. Am J Hum Genet 1996;59:471–474.
44.
American Society for Investigative Pathology (ASIP). Use of Human Tissues for Molecular Research. Bethesda, ASIP, 1996.
45.
Nuffield Council on Bioethics. Human Tissue: Ethical and Legal Issues. London, Nuffield Council, 1995.
46.
HUGO Statement on the Principled Conduct of Genetic Research. Genome Digest, May 1996.
47.
American Society of Human Genetics, Board of Directors, Statement on informed consent for genetic research. Am J Hum Genet 1996;59:471–474.
48.
European Group of Ethics. Opinion on Human Tissue Banking, 1998.
49.
Council of International Organizations for Medical Sciences (CIOMS) and WHO. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, WHO, 1993.
50.
World Health Organization, Declaration on the Promotion of Patients’ Rights in Europe. Copenhagen WHO Regional Office for Europe, 1994.
51.
Hirtle M: International policy positions on the banking and further use of human genetic material; in Knoppers BM, Caulfield T, Kinsella D (eds): Legal Rights and Human Genetic Material. Toronto, Emond-Montgomery, 1996, p 149.
52.
Markenstein LF: An analysis of the state of debate on the further use of human tissue in various European countries. Eur J Health Law 1995;2:125.
53.
Health Council of the Netherlands. Proper Use of Human Tissue. The Hague, 1994.
54.
Health Council of the Netherlands. Heredity, Science, and Society. The Hague, 1989.
55.
France, National Ethical Consultative Committee. Genetics and medicine: From prediction to prevention. Intl Digest Health Legisl 1996;47:263.
56.
Mazen NJ: Human DNA on trial in French law; in Knoppers BM, Laberge CM, Hirtle M (eds): Human DNA: Law and Policy. The Hague, Kluwer Law International, 1997, pp 43–54.
57.
Weir RF: Differing perspectives on consent, choice, and control; in Knoppers BM, Laberge CM, Hirtle M (eds): Human DNA: Law and Policy. The Hague, Kluwer Law International, 1997, pp 91–108.
58.
Weir RF, Horton JR: DNA Banking and Informed Consent. Part II. IRB: A review of human subjects research. IRB 1995;17(5/6):1–8.
59.
Levine RJ: Ethics and Regulation of Clinical Research, ed 2. Baltimore, Urban & Schwarzenberg, 1986.
60.
Advisory Committee on Human Radiation Experiments. Final Report. New York, Oxford University Press, 1996, pp 439–458.
61.
Thomas SB: Assessing differences in factors associated with participation in medical and public health research: A random household survey of black and white Americans. Funded by the Centers for Disease Control and Prevention, 1997.
62.
Department of Health and Human Services, Office of Inspector General: Institutional Review Boards: A Time for Reform. OEI-01-97-00193. Washington, June 1998.
63.
Merz JF, Sankar P: DNA banking: An empirical study of an informed consent form; in Weir RF (ed): Ethical and Legal Implications of Stored Tissue Samples, in press.
64.
Wertz DC: The difficulties of recruiting minorities to studies of ethics and values in genetics. Community Genet 1998;1:175–179.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.